Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
Please take into account the following.
https://www.lse.co.uk/rns/SAR/equity-fundraise-nlaqyaeq4r8ir0s.html
WRAP is limited to 300k as per RNS.
'It is a term of the WRAP Retail Offer that the total value of the WRAP Retail Offer Shares available for subscription at the Placing Price does not exceed £300,000.'
Regards
Breprocitinib was discontinued or to be more precise passed on to Priovant.
Breprocitinib Tyk2 Jak1
We are Tyk2 Jak1.
Difference here of vast importance is selectivity over.
Breprocitinib Tyk2 Jak1 around equal or 50 50
We are around 80% Tyk2 20% Jak 1 with Jak 1 being 4 to 5 fold over Jak2 and Jak3.
Interaction with Jaks
Jak1 is Tyk 2 and Jak3
Jak2 is Tyk 2 and Jak2
Jak3 will only pair with Jak1
Selectivity is all important as very difficult to gain sufficient degree of selectivity
Tyk 2 as an allosteric route can be considered as specific ( minimal ie over a thousand times more selective over other jaks.
We are informed that Jak 2 can have adverse off target effects.
Ropsacitinib an inhibitor now in development is a Tyk2 Jak2 inhibitor aimed at Psoriasis.
Very odd!
Allosteric Tyk2 albeit with good safety effects is not the be all and end all as was made out to be.
The pseudo domain that regulates the active site.
Good from a marketing point of view, nothing marvelous in Psoriasis as so many companies think they can do better of which ours is one.
Regulation over and actual contact with active site although sounding similar are streets apart.
Regards to all LTH and those genuinely newly aboard.
Good afternoon Potnak,
800 million not out of the question for 1801, 1802 l .think would need trialling but interestingly also is the recently added patent protection for 1802 in immuno therapy.
1 to 2 billion for the lot later this year is again not out of the question.
All that from a company that has MC of just under 8 million.
Have they become aware of other Indications outside of immuno oncology that 1802 may prove to be of benefit?
737 we need news on and as such have not included this in any value whatsover.
News on 737 direction would open doors to takeover l think. All compounds would be know about including Aurora + FLT3 which has its solubility issue preventing it to be administered by the oral route.
First things first is the 300k raise.
Regards
A link to a very long text below with regards to why 90% of drugs fail.
Not being negative here, it us just that l believe we have most of these areas now covered. Indeed we have already experienced some of them.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293739/
Very much undervalued Bobbler!
I put a value a while ago at 400 million at end of phase1 but people laugh and attempt to ridicule the idea.
Sits nicely in the table as where we are or will be if all goes well in this coming quarter.
The damage created by RF has been horrendous to say the least but it has not resulted in cessation of 1801 development or company closure forecast by some.
I am certain l will not get the amount of shares of the 300k raise as l would like.
Regards
Regards
Very good lengthy read Bobbler
Valuations
Pre clinic 88 million $ 57-119 million $
Phase1 399 million $ 211- 498 million $
Phase 2 734 million $ 436-930 million $
Phase3 1657 million $ 996-2527 million $
Approval 2496 million$ 1582- 3355 million $
End of preclinical 88 million
End of phase 1 399 million
Clearly it would not have been in Sares interest l believe to on licence at end of pre clinical.
Phase1 data results will add more meat to the bone and if we are fortunate to be able to raise funding then progress on phase 2 a.
Whilst a phase 2a trial does not have to include hundreds of patients to enable suitable statistical
analysis (accuracy is related to the magnitude of count) it will give a good indication as to the effectiveness of a compound.
We are not dealing with new kinase inhibitors.
The off target effects are known as from data on 1st generation poorly selective inhibitors.
Tyk2 has been given the all clear as per Deucravacitinib.
We now sit with a compound made up of the above known about molecules.
Are molecules are small that should enable absorption, all important distribution for the tissue involved on the indication with minimum effect on non targeted tissue, a low concentration in the blood stream that will enable minimal off target effects such as myocarditis ( heart ) and kidney damage. These are long term effects in areas of concern.
Our molecules are patented.
As the data and trial stage progress satisfactorily, then the value of the compound increases.
This will not necessarily be indicated by the current market cap as other factors involved ie finance, market sentiment and a degree of uncertainty.
It is not out of the question after satisfactory data shared between interested parties to recieve an offer of between 211 million$ to 490 million dollars plus later this year. These figures of course in dollars and represent also the lowest end of the scale. They may very well be considerably higher !
Pharmas patent protected pipelines are running short, inflation since report, as well as the demand for top end potential therapy will add value.
In addition we have 1802
Welcome comments on this.
Regards
Worthy of posting again, below is an extract from report which indicates at this stage the superiority of efficacy of 1801 over Deucravacitinib. Late preclinical stage admiitedly.
Interested to hear from any poster that the information is either false, misleading or not true.
'Both Tyk2 mutant mice and mice treated with SAR-20347 showed significant reduction of IL-6 and IL-17 in imiquimod-induced skin lesions, but only SAR-20347-treated mice presented reduced levels of IL-23, decreased keratinocyte proliferation and improved clinical score [22]. In addition, SAR-20347-treated mice manifested lower IL-17 gene expression compared to Tyk2 mutant mice [22]. In this model, Works et al. demonstrated that SAR-20347 treated mice showed an almost complete loss of IL-22 gene expression in skin lesions, and they postulate that SAR-20347 would impair the ability of Th17 and γδ cells to induce IL-22 [22]. IL-22 is required for development of autoreactive Th17 cells [77,78]. However, not only IL-22 production was impaired, since IL-22 signaling was also affected in vitro in a human colonic cell line, and STAT3 phosphorylation dependent of IL-22 was completely blocked [22].'
In addition
'Blocking both Tyk2 and Jak1 in this study was more effective than inhibition of Tyk2 alone at reducing psoriasis-like disease severity, keratinocyte proliferation, as well as IL-23, IL-17, IL-6, IL-22, and antimicrobial peptide gene expression, and the authors postulate that targeting a combination of Jak1 and Tyk2 using an orally available inhibitor may be a viable approach for treating psoriasis, but currently there are no ongoing or completed clinical trials for SAR-20347 [22].'
The above report from early 2023.'
Deucravacitinib the allosteric inhibitor does not interact with either Jak1 or Jak2 in the human body.
20347 is not a purely Tyk2
Regards.
Good.orning Damion,
A very pertinent post with link to.
Importantly SDC1802 granted further protection with patent for application in autoimmune.
Takeda 4 billion paid for Tyk2 inhibitor at phase2 stage.
If we took a modest risk factor and at one tenth of the price that equate to 400 million around 450p per share.
Raise additional funds for phase 2 or licence towards end of year.
Clearly the multiple ascending dose data is of the upmost importance.
All important LADMET information from human trials.
Very difficult to give an accurate prediction in preclinical even when 3 different animals involved but we can be reassured due to Deucravacitinib approved for use.
As for the remainder of the Jaks we can look at Baricitinib and although with black box warnings we have far greater selectivity of Jak1 over Jak2 and in addition we have a 4 to 5 fold selectivity of Tyk2 over Jak1.
According to Tim as he termed ,' we believe to be the optimal.amount'
I am certain 300k raise will be over subscribed.
I dont know if the HNWI'S will partake in this, but l not think that will make any difference if they do not.
All important safety data results can then be given to the interested parties.
When this is recieved the interested parties along with Tim and Co can discuss licensing deals or options and is the key time when formal offers leading to an on licence to occur.
Tim and Co here will have option to finance via fund raise or on licence.
Preferably l would like to see Sareum take 1801 into phase 2a first.
Regards
Puma l have never done 10,000 words a day you soppy little sod.
Grow up and get a life, you are clearly rattled.
Seek comfort over on ADVN.
You posted over 120 time pleading with people to sell.
Sareum have not gone bust despite the efforts of people like you. (At least 2 on ADVN)
Go over and chat to them.
You tried your best but alas you have failed. Clearly your best not good enough.
Now run along and be a nice little boy for mummy or you will.not get your Easter egg.
You are correct MegRS300.
Identical agendas to one or two here.
300k is not much to raise.
Will be eaten up.
The good thing is 1801 is progressing.
I believe we are better than most of the others and that includes Deucravacitinib.
Regards and have a great Easter weekend.